Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

David Wholley
Senior Vice President, Research Partnerships

June 12, 2020
The mission of the Foundation for the National Institutes of Health (FNIH) is to create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people’s lives.

The FNIH was created by Congress in 1990 as a not-for-profit charitable organization. The Foundation began its work in 1996 to facilitate groundbreaking research at the U.S. National Institutes of Health (NIH) and worldwide.

- Share resources
- Enable insight and innovation
- Establish standards
- Distribute expertise
- Create consensus
- Drive competitiveness in marketplace
- Disseminate knowledge
## Selected Public-Private Partnerships at the FNIH

<table>
<thead>
<tr>
<th>Partnership</th>
<th>Funding</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accelerating Medicines Partnership</strong></td>
<td>$302 million</td>
<td>NIH (OD), NIA, NIAMS, NIDDK, NINDS, 12 companies, 10 not-for-profit organizations</td>
</tr>
<tr>
<td><strong>Partnership for Accelerating Cancer Therapies</strong></td>
<td>$220 million</td>
<td>NCI, PhRMA, 12 pharmaceutical companies</td>
</tr>
<tr>
<td><strong>Alzheimer’s Disease Neuroimaging Initiative (ADNI)</strong></td>
<td>$206 million</td>
<td>NIA, NIBIB, 25+ companies, 3 not-for-profit organizations</td>
</tr>
<tr>
<td><strong>Grand Challenges in Global Health (GCGH)</strong></td>
<td>$201 million</td>
<td>Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td><strong>Lung-MAP: Master Lung Protocol Trial</strong></td>
<td>$163 million</td>
<td>NCI (SWOG), FDA, Friends of Cancer Research, 5 companies to date</td>
</tr>
<tr>
<td><strong>Vector-Based Control of Transmission (VCTR)</strong></td>
<td>$78 million</td>
<td>VRC/NIAID, Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td><strong>The Biomarkers Consortium</strong></td>
<td>$95 million</td>
<td>FDA, NIH, CMS, PhRMA, BIO, pharmaceutical and nutrition companies, not-for-profit organizations</td>
</tr>
<tr>
<td><strong>Comprehensive T Cell Vaccine Immune Monitoring Consortium (CT-VIMC)</strong></td>
<td>$50 million</td>
<td>Bill &amp; Melinda Gates Foundation, NIAID</td>
</tr>
<tr>
<td><strong>MAL-ED: The Interactions of Malnutrition and Enteric Infections, Effect on Childhood Development</strong></td>
<td>$46 million</td>
<td>Bill &amp; Melinda Gates Foundation, Fogarty Institute Center (NIH)</td>
</tr>
</tbody>
</table>
On April 17, NIH announced the launch of a public-private partnership, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), to develop a coordinated research response to speed COVID-19 treatment and vaccine options.
Coordinated by the Foundation for the National Institutes of Health (FNIH), **ACTIV brings together multiple partners from government, industry, and non-profits:**

<table>
<thead>
<tr>
<th>7 Government Partners</th>
<th>18 Industry Partners</th>
<th>3 Nonprofits</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARDA</td>
<td>AbbVie</td>
<td>Bill &amp; Melinda Gates Foundation</td>
</tr>
<tr>
<td>CDC</td>
<td>Amgen</td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td>DoD</td>
<td>AstraZeneca</td>
<td>RTI International</td>
</tr>
<tr>
<td>EMA</td>
<td>Bristol Myers Squibb</td>
<td></td>
</tr>
<tr>
<td>FDA</td>
<td>Eisai</td>
<td></td>
</tr>
<tr>
<td>NIH</td>
<td>Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td>VA</td>
<td>Evotec</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilead</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KSQ Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Merck</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roche-Genentech</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Takeda</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vir Biotechnology</td>
<td></td>
</tr>
</tbody>
</table>
ACTIV is dedicated to:

- Establishing a **collaborative framework** for prioritizing therapeutic candidates and accelerating vaccine evaluation
- Accelerating clinical trials of promising agents and leveraging existing clinical trial networks while maintaining rigorous safety standards
- Coordinating regulatory processes and leveraging assets among all partners
The ACTIV partnership consists of four fast-track focus areas, each of which is led by a working group:

- Preclinical
- Therapeutics - Clinical
- Clinical Trial Capacity
- Vaccines
ACTIV Governance includes representation from all stakeholders

ACTIV Executive Committee

**Co-Chairs**
- Francis Collins, NIH
- Paul Stoffels, J&J

**Members**
- Anthony Fauci, NIAID
- Gary Gibbons, NHLBI
- Janet Woodcock, OWS
- William Pao, Roche
- Mikael Dolsten, Pfizer
- Gary Disbrow, BARDA
- Peter Marks, FDA
- Andrew Plump, Takeda

ACTIV Partnership Leadership Group

Preclinical Working Group
- Sub Groups:
  - Animal Models
  - In Vitro Assays

Therapeutics Clinical Working Group
- Sub Groups:
  - Agent Prioritization
  - Master Protocol

Clinical Trial Capacity Working Group
- Sub Groups:
  - Survey Development
  - Clinical Trial Network Inventory
  - Innovations

Vaccines Working Group
- Sub Groups:
  - Vaccines Clinical Trials
  - Protective Immune Responses
  - Vaccine-Associated Immune Enhancement

ACTIV Database & Inventory Effort

Co-Chairs:
- Francis Collins, NIH
- Paul Stoffels, J&J

Members:
- Anthony Fauci, NIAID
- Gary Gibbons, NHLBI
- Janet Woodcock, OWS
- William Pao, Roche
- Mikael Dolsten, Pfizer
- Gary Disbrow, BARDA
- Peter Marks, FDA
- Andrew Plump, Takeda

Sub Groups:
- Animal Models
- In Vitro Assays

Therapeutics Working Group
- Sub Groups:
  - Agent Prioritization
  - Master Protocol

Clinical Trial Capacity Working Group
- Sub Groups:
  - Survey Development
  - Clinical Trial Network Inventory
  - Innovations

Vaccines Working Group
- Sub Groups:
  - Vaccines Clinical Trials
  - Protective Immune Responses
  - Vaccine-Associated Immune Enhancement
Operation Warp Speed/Therapeutics and ACTIV are working together

**Board of directors**
Secretaries of HHS and DoD (co-chairs), and representatives from VA, USDA, OSTP, OMB, NSC

**Operation Warp Speed**
- Program Management and Communications
- Overall lead
- Diagnostics
  - Scientific Leads
  - Clinical Leads
  - Supply and Distribution Leads
  - Project management
- Vaccines
  - R&D Leads
  - Clinical Leads
  - Supply and Distribution Leads
  - Project management
- Therapeutics
  - Scientific Leads
  - Clinical Leads
  - Supply and Distribution Leads
  - Project management

**ACTIV**
- ACTIV Executive Team (co-chairs and members)
- ACTIV Leadership Team
- Therapeutics
  - Clinical
    - Working Group Co-Chairs
  - Preclinical
    - Working Group Co-Chairs
- Clinical Trial Capacity
  - Working Group Co-Chairs
- Vaccines
  - Working Group Co-Chairs
<table>
<thead>
<tr>
<th>Establishing a centralized process and repository for harmonizing and sharing methods and evaluating animal models</th>
<th>Increasing access to validated animal models</th>
<th>Extending access to high-throughput screening facilities, especially in biosafety level 3 (BSL-3) labs</th>
<th>Enhancing comparison of approaches to identify informative assays</th>
</tr>
</thead>
<tbody>
<tr>
<td>The working group is standardizing and sharing preclinical evaluation methods in an open forum that allows for comparison and validation by:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Preclinical**

The working group is standardizing and sharing preclinical evaluation methods in an open forum that allows for comparison and validation by:

- Establishing a centralized process and repository for harmonizing and sharing methods and evaluating animal models
- Increasing access to validated animal models
- Extending access to high-throughput screening facilities, especially in biosafety level 3 (BSL-3) labs
- Enhancing comparison of approaches to identify informative assays
ACTIV Preclinical Working Group Accomplishments to Date

✓ Completed
  o In progress

PRECLINICAL

✓ Developed a master inventory of preclinical testing resources [will be available as part of the NCATS Open Science Portal by early July 2020]

✓ Established SOPs for accelerated preclinical agent development in response to a pandemic [manuscript to be submitted by the end of June 2020]

✓ Developed a National Strategy for NHP Research [Coordinating Committee established by end of July 2020]

✓ Established a process for prioritizing in vitro assays and evaluating preclinical compounds
  o Establish a virtual preclinical in vitro and in vivo testing network for therapeutic sponsors to access preferred or limited resources [late summer 2020]
  o Create a public database for sharing preclinical data [available in late summer 2020]
**Therapeutics - Clinical**

The working group is dedicated to prioritizing and accelerating clinical evaluation of therapeutic candidates with near-term potential by:

<table>
<thead>
<tr>
<th>Establishing a steering committee with relevant expertise and objectivity to set criteria for and rank potential candidates submitted by industry partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developing a complete inventory of potential candidates with different mechanisms of action and acceptable safety profiles</td>
</tr>
<tr>
<td>Designing, launching, and openly sharing master protocols with agreed-upon endpoints, sampling, and analysis for evaluating candidates</td>
</tr>
<tr>
<td>Using a single control arm to enhance trial efficiency</td>
</tr>
</tbody>
</table>
# Agent Prioritization Overview

<table>
<thead>
<tr>
<th>Source Candidates</th>
<th>Publicly Available Data</th>
<th>Submission from Investigators</th>
<th>Survey Responses</th>
</tr>
</thead>
</table>

## Clinical Agents

- **Antivirals**
- **Host Targeted / Immunomodulators**
- **Symptomatic / Supportive**
- **Neutralizing mAbs**

## Prioritization Activities

- Score Candidates based on Pre-defined Criteria
- Assess Supply and Other Logistical Needs
- Develop Minimum Entry Criteria
**ACTIV is Developing a Portfolio of Master Protocol Clinical Trials**

OWS/ACTIV Therapeutics has been taking a portfolio approach to address the dramatic health and economic challenges posed by the pandemic, with harmonized efforts that address disease etiology and symptomology.

<table>
<thead>
<tr>
<th>ACTIV</th>
<th>Details</th>
</tr>
</thead>
</table>
| **ACTIV-1** | • Inpatient, >18 years, COVID+  
  • Phase III - ~2000 patients  
  • **3 Host-targeted Immune Modulators**  
  • Targets - TNFα, CTLA-4, CCR2/CCR5  
  • CRO  
  • US + Global (if needed)  
  • Projected to Launch in late June |
| **ACTIV-2** | • Outpatient, >18 years, COVID+  
  • Phase II/III – 110 patients (Phase 2)/900 patients (Phase 3) per agent  
  • **SARS-CoV-2 Neutralizing Monoclonal Antibodies**  
  • NIAID ACTG + CRO  
  • US + Global (Targeting South America)  
  • Projected to Launch in early July |
| **ACTIV-3** | • Inpatient, >18 years, COVID+  
  • Phase III – 150 patients (Stage 1)/506 patients (Stage 2) per agent  
  • **SARS-CoV-2 Neutralizing Monoclonal Antibodies**  
  • NIAID INSIGHT + NHLBI PETAL + CRO  
  • US + Global (Targeting South America)  
  • Projected to Launch in mid-July |
| **ACTIV-4** | • Inpatient, >18 years, COVID+  
  • Phase II/III Master Protocol – TBD patients  
  • **3 Anticoagulants (leading to Anticoagulant + Immune Modulator Combos)**  
  • NHLBI-NINDS “Master” Network  
  • US  
  • Projected to Launch in late June |
| **ACTIV-5** *(TBD)* | • De Novo Master Protocol  
  • **Promising Agents Not Evaluated Elsewhere (e.g., Antivirals)**  
  • Network TBD  
  • Projected Launch TBD |
ACTIV Therapeutics Clinical Working Group Accomplishments to Date

✓ Completed
  o In progress

**THERAPEUTICS CLINICAL**

✓ Developed a **process for prioritizing clinical agents** for rapid testing (April 2020)

✓ Evaluated hundreds of publicly available agents and **prioritized promising compounds for study**
  (1 Wave Finalized in May 2020 and designated to master protocols)

✓ **Assessed, designed, and harmonized multiple master protocols** for ACTIV clinical trials (April-June 2020)

✓ **Selected clinical trial networks** best suited for master protocols (May 2020)
  o Launch multiple clinical trials using candidates selected
  o Prioritize additional agents for study (Beginning June 2020 – performed on a rolling basis)
Clinical Trial Capacity

The working group is maximizing clinical trial capacity and effectiveness by connecting existing networks of clinical trials and leveraging capabilities, including:

| Specializing in different populations and disease stages | Using infrastructure and expertise from across multiple NIH and non-NIH networks and clinical research organizations | Establishing a coordination mechanism across networks to expedite trials | Tracking incidence across sites and projecting future capacity |
Mandate: Develop a full inventory of clinical trial capacity, including networks of NIH ICs, industry, and other organizations, that will serve as a guide for the settings in which to implement effective COVID-19 clinical trials

Clinical Trial Capacity Working Group Accomplishments to Date

- Identified 80+ novel and scalable enhancements / efficiencies for Tx clinical protocols, MAb protocols, vaccine protocols

- Three unique clinical trial capacity surveys developed for Networks, Sites, and Clinical Research Organizations (CROs) and Site Management Organizations (SMOs)
  - 53 Networks have completed the survey*
  - 640 total Sites have completed the survey*
  - 35 CROs/SMOs have completed the survey*
  *Additional organizations will be surveyed as identified

- A Tableau-based dashboard has been created to query and visualize survey data
- Clinical Trial network, site, and CRO/SMO survey data is combined in one comprehensive view

- Overlay of data indicating: 1) days until peak hospitalization from University of Pennsylvania, 2) confirmed COVID cases (7-day moving average) from Johns Hopkins University (JHU) and 3) confirmed COVID deaths (7-day moving average) from JHU with clinical trial capacity survey data to optimize therapeutics and vaccine site selection
ACTIV Clinical Trial Capacity Working Group Accomplishments

✓ Completed
  ○ In progress

CLINICAL CAPACITY

✓ Developed and launched clinical trial capacity surveys
✓ Collected clinical capacity data for federal networks, industry, academic, Clinical Research Organizations (CROs) and Site Management Organizations (SMOs)
✓ Identified innovations to enable safe and rapid execution of clinical trials
✓ Establish ACTIV clinical trial capacity recommendations committees
The working group is charged with accelerating evaluation of vaccine candidates to enable rapid authorization or approval.

The group will create a collaborative framework to share insights into natural immunity and vaccine candidate–induced immune response involving:

- Evaluating protective immune response from natural history and neutralizing antibody studies
- Establishing protocols for sampling and analyses and reagents
- Understanding evidence for vaccine-associated immune enhancement of disease
- Engaging with regulators on evidence to support vaccine authorization

Efficacy trials will be harmonized to enable analysis of correlates of protection across vaccines.
ACTIV Vaccine Working Group Accomplishments to Date

✓ Completed
  o In progress

VACCINES

✓ Developed harmonized vaccine protocols to enable analyses of correlates of protection across trials (to be executed by OWS/NIH/BARDA)

✓ Assessed protective immune response evidence to support accelerated use or approval of vaccine candidates

✓ Articulated scientific and operational challenges of developing controlled human infection models (manuscript submitted for publication)

  o Evaluate implications of evidence on immune-associated disease enhancement for COVID-19 vaccine development (manuscript expected to be submitted by June 30)
<table>
<thead>
<tr>
<th><strong>ACTIV Accomplishments</strong></th>
<th>✓ <strong>Completed</strong></th>
<th>✓ <strong>In progress</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Developed a master inventory of preclinical testing resources</td>
<td>✓ Established SOPs for accelerated preclinical agent development in response to a pandemic</td>
<td>✓ Developed a National Strategy for NHP Research</td>
</tr>
<tr>
<td>✓ Established a process for prioritizing in vitro assays and evaluating preclinical compounds</td>
<td>✓ Create a public database for sharing preclinical data</td>
<td>✓ Establish a process for prioritizing in vitro assays and evaluating preclinical compounds</td>
</tr>
</tbody>
</table>

### PRECLINICAL

#### Developed a master inventory of preclinical testing resources

- ✓ Developed a master inventory of preclinical testing resources
- ✓ Established SOPs for accelerated preclinical agent development in response to a pandemic
- ✓ Developed a National Strategy for NHP Research
- ✓ Established a process for prioritizing in vitro assays and evaluating preclinical compounds
  - ✓ Create a public database for sharing preclinical data

### THERAPEUTICS CLINICAL

#### Developed a process for prioritizing clinical agents for rapid testing

- ✓ Developed a process for prioritizing clinical agents for rapid testing
- ✓ Evaluated hundreds of publicly available agents and prioritized promising compounds for study
- ✓ Assessed, designed, and harmonized multiple master protocols for ACTIV clinical trials
- ✓ Selected clinical trial networks best suited for master protocols
  - ✓ Launch multiple clinical trials using candidates selected
  - ✓ Prioritize additional agents for study

### CLINICAL CAPACITY

#### Developed and launched clinical trial capacity surveys

- ✓ Developed and launched clinical trial capacity surveys
- ✓ Collected clinical capacity data for federal networks, industry, academic, Clinical Research Organizations (CROs) and Site Management Organizations (SMOs)
- ✓ Identified innovations to enable safe and rapid execution of clinical trials
  - ✓ Establish ACTIV clinical trial capacity recommendations committees

### VACCINES

#### Developed harmonized vaccine protocols to enable analyses of correlates of protection across trials

- ✓ Developed harmonized vaccine protocols to enable analyses of correlates of protection across trials
- ✓ Assessed protective immune response evidence to support accelerated use or approval of vaccine candidates
  - ✓ Articulated scientific and operational challenges of developing controlled human infection models
  - ✓ Evaluate implications of evidence on immune-associated disease enhancement for COVID-19 vaccine development
Where do I go for more information on ACTIV?

For general information:

 ✓ NIH ACTIV Website [https://www.nih.gov/research-training/medical-research-initiatives/activ]


To submit ideas, general information on assays or agents, or candidate agents, and queries:


For formal submission of agents for testing in ACTIV: